Association Between Serum Iron Biomarkers and Breast Cancer.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
02 2021
Historique:
received: 28 05 2020
revised: 10 08 2020
accepted: 03 12 2020
pubmed: 10 12 2020
medline: 4 1 2022
entrez: 9 12 2020
Statut: ppublish

Résumé

Iron is both essential to life and potentially toxic at higher levels. Epidemiologic studies of iron and breast cancer are sparse, with substantial heterogeneity found in a recent meta-analysis. Evidence based on a comprehensive set of iron biomarkers and a large sample size could help clarify relationships between iron body stores and breast cancer risk. A case-cohort sample of 6,008 women, including 3,011 incident cases, has been followed for a median of 7.9 years. We estimated breast cancer HRs with Cox models, including age as the primary time scale and including in turn iron, ferritin, percent transferrin saturation, and their first principal component (PC) both as categorical (quartiles) and continuous measures. Adjusted HRs for the highest versus lowest quartiles of iron, ferritin, and transferrin saturation (95% confidence interval) were 1.06 (0.90-1.25), 1.03 (0.87-1.23), and 0.94 (0.80-1.12), respectively, and 1.06 (0.90-1.25) for the first principal component (PC). Associations were similar when follow-up time was restricted to ≤4 or >2 years. A study with one of the largest sample sizes to date and with all three measures of circulating iron, ferritin, and transferrin saturation does not support a strong association between elevated iron stores and breast cancer risk. Further investigation of low iron may be warranted. These results do not support a strong association between iron overload and breast cancer incidence.

Sections du résumé

BACKGROUND
Iron is both essential to life and potentially toxic at higher levels. Epidemiologic studies of iron and breast cancer are sparse, with substantial heterogeneity found in a recent meta-analysis. Evidence based on a comprehensive set of iron biomarkers and a large sample size could help clarify relationships between iron body stores and breast cancer risk.
METHODS
A case-cohort sample of 6,008 women, including 3,011 incident cases, has been followed for a median of 7.9 years. We estimated breast cancer HRs with Cox models, including age as the primary time scale and including in turn iron, ferritin, percent transferrin saturation, and their first principal component (PC) both as categorical (quartiles) and continuous measures.
RESULTS
Adjusted HRs for the highest versus lowest quartiles of iron, ferritin, and transferrin saturation (95% confidence interval) were 1.06 (0.90-1.25), 1.03 (0.87-1.23), and 0.94 (0.80-1.12), respectively, and 1.06 (0.90-1.25) for the first principal component (PC). Associations were similar when follow-up time was restricted to ≤4 or >2 years.
CONCLUSIONS
A study with one of the largest sample sizes to date and with all three measures of circulating iron, ferritin, and transferrin saturation does not support a strong association between elevated iron stores and breast cancer risk. Further investigation of low iron may be warranted.
IMPACT
These results do not support a strong association between iron overload and breast cancer incidence.

Identifiants

pubmed: 33293341
pii: 1055-9965.EPI-20-0715
doi: 10.1158/1055-9965.EPI-20-0715
pmc: PMC7867615
mid: NIHMS1653940
doi:

Substances chimiques

Biomarkers 0
Iron E1UOL152H7

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

422-425

Subventions

Organisme : Intramural NIH HHS
ID : Z01 ES044005
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA ES102245
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA ES103066
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Cancer Epidemiol Biomarkers Prev. 2014 Mar;23(3):516-24
pubmed: 24443403
Annu Rev Nutr. 2018 Aug 21;38:97-125
pubmed: 30130469
Environ Health Perspect. 2017 Dec 20;125(12):127003
pubmed: 29373861
BMC Cancer. 2019 Jun 6;19(1):543
pubmed: 31170936
BMC Cancer. 2017 Oct 23;17(1):692
pubmed: 29058598

Auteurs

Ann Von Holle (A)

Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

Katie M O'Brien (KM)

Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

Dale P Sandler (DP)

Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

Robert Janicek (R)

Advanced Research and Diagnostic Laboratory, University of Minnesota, Minneapolis, Minnesota.

Clarice R Weinberg (CR)

Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina. weinberg@niehs.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH